Haemonetics (NYSE:HAE) this week appointed James D’Arecca as chief financial officer, effective on April 11. D’Arecca will oversee the company’s treasury, controllership and accounting, investor relations, tax, information technology and financial planning and analysis functions. He will report directly to president and CEO Chris Simon. He succeeds William Burke who will remain with Haemonetics in an […]
Haemonetics
Haemonetics posts mixed-bag Q3, tightens guidance range
Haemonetics (NYSE:HAE) shares dipped slightly before hours on third-quarter results that were mixed compared to the consensus forecast. The Boston-based company posted profits of $23.2 million, or 45¢ per share, on sales of $259.8 million for the three months ended Jan. 1, 2022, for a 27.1% bottom-line slide on sales growth of 8.1%. Adjusted to […]
Haemonetics wins FDA nod for same-day discharge following AFib ablation using Vascade MVP
Haemonetics today said that it has received FDA approval for same-day discharge after atrial fibrillation ablation using its Vascade MVP venous vascular closure system. Vascade MVP is a vascular closure system that is designed for procedures that require multiple access site venous closures. It uses 6 to 12 Fr inner diameter sheaths that are commonly […]
Haemonetics ticks up on Street-beating Q1 results
Haemonetics (NYSE:HAE) posted first-quarter results this week that beat the overall consensus on Wall Street. The Boston-based hematology device company reported losses of -$4.5 million, or -9¢ per share, on sales of $228.5 million for the three months ended July 3, for a sales growth of 16.85% compared with Q1 2021. Adjusted to exclude one-time items, […]
Report: Medtech dollars, deals hit new highs in first half of 2021
Fueled at least in part by exceptionally strong IPO and M&A markets, hedge funds, venture capitalists, private equity firms and corporate investors are committing more time and money into privately held medical devices companies, according to a new “Healthcare Investments and Exits” report issued by Silicon Valley Bank. The report examining the first half of […]
Haemonetics plummets on mixed-bag Q4 results
Haemonetics (NYSE:HAE) posted fourth-quarter results today that beat the revenue consensus on Wall Street and missed on earnings estimates. The company reported losses of -$11 million, or -22¢ per share, on sales of $225 million for the three months ended April 3, for a sales loss of -5.65% compared with Q4 2021. Adjusted to exclude one-time […]
Haemonetics up 18% on Street-beating Q3 results
Haemonetics (NYSE:HAE) posted third-quarter results today that beat the consensus forecast on Wall Street, sending its shares up. The Boston-based hematology tech company reported profits of $31.9 million, or 62¢ per share, on sales of $240.4 million for the three months ended Dec. 26, 2020, for a bottom-line gain of 6.6% sales loss of -7.2% compared […]
MedTech 100 roundup: Another peak for the industry
Medtech stocks have been on the rise in 2021, and the past week saw the trend continue with yet another all-time best mark. MassDevice‘s MedTech 100 index reached 107.4 points on Jan. 20, topping the all-time best of 106.81 points set on Jan. 8. That mark represents a 16% jump from the pre-pandemic high of 92.32 […]
Haemonetics to acquire Cardiva
Haemonetics (NYSE:HAE) announced today that it entered into a definitive agreement to acquire Cardiva Medical for $475 million. Boston-based Haemonetics’ agreement includes an upfront cash payment of $475 million at closing, along with up to an additional $35 million in contingent consideration based on sales growth, according to a news release. The acquisition is subject to […]
Haemonetics posts Street-beating Q2
Haemonetics (NYSE:HAE) shares dipped slightly on second-quarter results that topped the consensus forecast. The Boston-based blood management technology developer posted profits of $48.1 million, or 94¢ per share, on sales of $209.5 million for the three months ended Sept. 26, 2020, for a 28.3% bottom-line gain on a sales decline of -17.1%. Adjusted to exclude one-time […]
FDA clears Haemonetics’ plasma collection system
Haemonetics (NYSE:HAE) announced that it received FDA 510(k) clearance for its NexSys PCS system with Persona technology. Boston-based Haemonetics’ new, proprietary Persona technology customizes plasma collection based on an individual donor’s body composition, according to a news release. NexSys PCS (plasma collection system) with Persona is intended for use as an automated cell separator system and […]